Qureight, an end-to-end imaging CRO, has partnered with Mediar Therapeutics to support their Phase 2 trial of MTX-474 in diffuse cutaneous systemic sclerosis (dcSSc). This collaboration aims to revolutionize the understanding and treatment of a complex disease characterized by fibrosis, vasculopathy, and inflammation in the lungs, skin, and other vital organs. Qureight's cutting-edge AI-powered 3D quantitative imaging analytics platform will be utilized to analyze High-Resolution Computed Tomography (HRCT) images, providing a comprehensive view of changes in compartment-specific lung biomarkers.
The trial, Mediar's EncompaSSc, is a randomized, double-blind, placebo-controlled study designed to investigate the safety and efficacy of MTX-474 in dcSSc patients. MTX-474 is a first-in-class human monoclonal antibody that targets EphrinB2, a key protein driving fibrosis in SSc. By using Qureight's advanced imaging models, the study will assess changes in lung biomarkers, offering a detailed understanding of disease activity and therapeutic response.
Qureight's platform employs multiple imaging models: Glass8™ for inflammatory signal assessment, Fibr8™ for fibrotic change quantification, Vascul8™ for pulmonary vascular evaluation, Air8™ for airway analysis, and Lung8™ for comprehensive lung structural assessment. These models collectively provide a nuanced, compartment-specific perspective on disease activity and progression in SSc. The platform's strength lies in its ability to generate immediate, highly detailed insights, surpassing traditional image-based analysis.
SSc is associated with significant morbidity and mortality, underscoring the critical need for innovative therapeutics to halt disease progression. MTX-474's unique mechanism of action, targeting EphrinB2, presents a promising avenue for treatment. Mediar's trial aims to evaluate the safety and efficacy of MTX-474, offering hope for improved outcomes in dcSSc patients.
Jessica Payne, Chief Commercial Officer at Qureight, emphasizes the platform's capability to deliver precise, compartment-specific insights into lung disease. She highlights the comprehensive view of lung anatomy provided by Qureight's suite of models, each contributing to a deeper understanding of disease activity and progression in SSc. Jeff Bornstein, Chief Medical Officer at Mediar Therapeutics, expresses enthusiasm for the partnership, emphasizing the potential of Qureight's AI-driven imaging endpoints to enhance understanding of disease mechanisms and treatment response in SSc.
This collaboration between Qureight and Mediar Therapeutics marks a significant advancement in the field of fibrotic diseases, particularly systemic sclerosis. By leveraging Qureight's innovative imaging platform, the trial aims to provide valuable insights into the pulmonary manifestations of SSc, potentially leading to more effective treatment strategies and improved patient outcomes.
